Lido Advisors LLC Sells 15,565 Shares of Pfizer Inc. (NYSE:PFE)

Lido Advisors LLC trimmed its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 4.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 335,424 shares of the biopharmaceutical company's stock after selling 15,565 shares during the quarter. Lido Advisors LLC's holdings in Pfizer were worth $8,899,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Norges Bank purchased a new position in Pfizer in the 4th quarter worth approximately $2,328,986,000. Charles Schwab Investment Management Inc. lifted its stake in Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Raymond James Financial Inc. bought a new position in Pfizer in the 4th quarter worth about $274,694,000. Massachusetts Financial Services Co. MA raised its stake in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares in the last quarter. Finally, APG Asset Management N.V. lifted its holdings in Pfizer by 1,106.0% in the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock worth $143,967,000 after purchasing an additional 5,153,257 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, Pfizer has an average rating of "Moderate Buy" and a consensus target price of $29.64.

Pfizer Trading Up 2.6 %

Shares of PFE traded up $0.62 on Wednesday, reaching $24.41. 53,879,535 shares of the company's stock were exchanged, compared to its average volume of 40,882,811. The business has a 50 day moving average price of $24.44 and a two-hundred day moving average price of $25.85. The stock has a market capitalization of $138.44 billion, a P/E ratio of 17.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the prior year, the company earned $0.82 earnings per share. The business's quarterly revenue was down 7.8% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.05%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 121.99%.

Insider Activity

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.